Trial · NCT07603037
EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure
NCT07603037, Not applicable, Not yet recruiting, First Affiliated Hospital of Wannan Medical College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure. Trials, record NCT07603037. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07603037
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure
- NCT number
- NCT07603037
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 12 participants, estimated
- Lead sponsor
- First Affiliated Hospital of Wannan Medical College
- Conditions
- Acute Respiratory Failure (ARF), Hypertension, Pulmonary Perfusion Imbalance, Aortic Dissection (Subset)
- Interventions
- Nitroglycerin, Nicardipine
- First posted
- 2026-05-22
- Last updated
- 2026-07-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Ventilation-Perfusion Matching Index | Baseline (prior to infusion), 30 minutes after infusion initiation, 60 minutes after infusion initiation. | The ventilation-perfusion matching index quantifies the correlation between regional ventilation and perfusion signals derived from EIT imaging. The index ranges from 0 to 1; higher values indicate better matching. |
| Primary | Change in Physiological Dead Space Fraction (Vd/Vt) | Baseline, 30 minutes, and 60 minutes. | Physiological dead space is calculated as (PaCO₂ - PeCO₂)/PaCO₂, supplemented by EIT-based regional ventilation analysis. The expected range is 0 to 0.8; higher values indicate greater alveolar wastage and poorer gas exchange. |
| Primary | Change in Intrapulmonary Shunt Fraction (%) | Baseline, 30 minutes, and 60 minutes. | The shunt fraction represents the percentage of non-oxygenated blood flowing through the lungs without gas exchange. It is computed as Qs/Qt = (CCO₂ - CaO₂) / (CCO₂ - CvO₂), approximated by EIT regional perfusion measurement. Typical range 0-40 %; higher values indicate worse oxygenation efficiency. |
| Secondary | Change in Pulmonary Perfusion Distribution | Baseline, 30 minutes, and 60 minutes. | Regional perfusion ratio analyzed via EIT contrast impedance variation after saline bolus indicator; expressed as percentage of dependent to non-dependent lung regions. Higher ratios reflect more homogeneous perfusion. |
| Secondary | Change in Pulmonary Ventilation Distribution | Baseline, 30 minutes, and 60 minutes. | Regional ventilation heterogeneity index calculated from EIT ventilation waves; value ranges 0-1, where higher values represent less homogeneous ventilation. |
| Secondary | Change in Oxygenation Index (PaO₂/FiO₂ Ratio) | Baseline, 30 minutes, and 60 minutes. | Ratio of arterial oxygen partial pressure to fraction of inspired oxygen, unit mmHg; range ≤ 300 mmHg inclusion criterion; higher values indicate better oxygen exchange. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07603037
GET https://conductscience.org/api/trials/v1/NCT07603037/registered